, Geneva: World Health Organization, WHO. Yellow fever fact sheet, 2019.
Yellow fever, J Clin Virol, vol.64, pp.160-73, 2015. ,
Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data, PLoS Med, vol.11, p.1001638, 2014. ,
Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis, Lancet Infect Dis, vol.17, pp.1209-1226, 2017. ,
, Vaccines and vaccination against yellow fever: WHO position paper, Vaccine, vol.33, pp.76-77, 2013.
Questions regarding the safety and duration of immunity following live yellow fever vaccination, Expert Rev Vaccines, vol.15, pp.1519-1552, 2016. ,
, Collaborative Group for Studies of Yellow Fever Vaccination. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old, Mem Inst Oswaldo Cruz, vol.110, pp.771-80, 2015.
Neutralizing antibody response to booster vaccination with the 17D yellow fever vaccine, Vaccine, vol.24, pp.2843-2892, 2006. ,
Yellow fever 17D vaccine safety and immunogenicity in the elderly, Hum Vaccin, vol.1, pp.207-221, 2005. ,
Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study, Vaccine, vol.36, pp.4112-4129, 2018. ,
17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients, J Infect, vol.72, pp.713-735, 2016. ,
Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline, BMC Infect Dis, vol.14, p.391, 2014. ,
Recommended tests for association in 2×2 tables, Stat Med, vol.28, pp.1159-75, 2009. ,
Improving the reporting of P-values generated by randomization methods, Methods Ecol Evol, vol.4, pp.1033-1069, 2013. ,
Immunogenicity of yellow fever vaccine coadministered with MenAfriVac in healthy infants in Ghana and Mali, Clin Infect Dis, vol.61, issue.5, pp.586-93, 2015. ,
, Geneva: World Health Organization, WHO. International health regulations, 2005.
Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years, Am J Trop Med Hyg, vol.89, pp.434-478, 2013. ,
Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, MMWR Morb Mortal Wkly Rep, vol.64, pp.647-50, 2015. ,
Is a dose of 17D vaccine in the current context of yellow fever enough?, Braz J Microbiol, vol.49, pp.683-84, 2018. ,
Single shot of 17D vaccine may not confer life-long protection against yellow fever, Mem Inst Oswaldo Cruz, vol.113, pp.135-172, 2018. ,
Yellow fever vaccinationonce in a lifetime, Travel Med Infect Dis, vol.15, pp.1-2, 2017. ,
Yellow fever vaccination: is one dose always enough, Travel Med Infect Dis, vol.11, pp.266-73, 2013. ,
, Grading of recommendations, assessment, development, and evaluation (GRADE) for yellow fever vaccine booster doses, Centers for Disease Control and Prevention, 2015.
, Eliminate yellow fever epidemics (EYE): a global strategy, Wkly Epidemiol Rec, vol.92, pp.193-204, 2017.
The 17D-204 vaccine strain-induced protection against virulent yellow fever virus is mediated by humoral immunity and CD4+ but not CD8+ T cells, PLoS Pathog, vol.12, p.1005786, 2016. ,
Booster dose after 10 years is recommended following 17DD-YF primary vaccination, Hum Vacc Immunother, vol.12, pp.491-502, 2016. ,
,
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine, J Clin Invest, vol.124, pp.3147-58, 2014. ,
Yellow fever outbreak. DREF operation n° MDRGH005. International Federation of Red Cross and Red Crescent Societies, 2012. ,
Pathogenesis and pathophysiology of yellow fever, Adv Virus Res, vol.60, pp.343-95, 2003. ,
Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination, Sci Rep, vol.7, p.662, 2017. ,
Study of combined vaccination against yellow fever and measles in infants from six to nine months, J Biol Stand, vol.17, pp.9-15, 1989. ,
Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine, Vaccine, vol.17, pp.1042-1048, 1999. ,
Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine, Bull World Health Organ, vol.59, pp.895-900, 1981. ,
CHRONOVAC VOYAGEUR: a study of the immune response to yellow fever vaccine among infants previously immunized against measles, Vaccine, vol.35, pp.6166-71, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01702891
Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella, Vaccine, vol.29, pp.6327-6361, 2011. ,
Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?, Vaccine, vol.33, pp.2301-2307, 2015. ,
Comparison of the immunogenicity and safety of two 17D yellow fever vaccines, Am J Trop Med Hyg, vol.60, pp.1045-50, 1999. ,
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial, Am J Trop Med Hyg, vol.66, pp.533-574, 2002. ,
Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan, Trop Med Int Health, vol.11, pp.1529-1570, 2006. ,
, Ghana. ISRCTN registry number ISRCTN82484612
, double-blind, randomised, controlled, dose ranging study to evaluate the safety, immunogenicity, dose response and schedule response of a meningococcal A conjugate vaccine administered concomitantly with local expanded program on immunisation (EPI) vaccines in healthy infants. 2. Pers-007 (phase IV), Ghana. ISRCTN registry number ISRCTN10763234
, Evaluation of antibody persistence in Ghanaian children more than five years after vaccination with MenAfriVac ® widely used in Sub-Saharan Africa to prevent epidemic meningitis
, Mali. Pan African Clinical Trials Registry number PACTR201110000328305 URL
double-blind, randomized, controlled study to evaluate the immunogenicity and safety of different schedules and formulations of a meningococcal A conjugate vaccine administered concomitantly with local EPI vaccines in healthy infants and toddlers ,
, Pers-007 (phase IV), Mali. ISRCTN registry number ISRCTN37623829 URL
, Long-term follow-up of children who participated at 9-12 months of age in clinical trial PsA-TT-007 in Mali
Permutation tests: a practical guide to resampling methods for testing hypotheses, 2000. ,
Improving the reporting of P-values generated by randomization methods, Methods Ecol Evol, vol.4, pp.1033-1039, 2013. ,